Effect of diabetes on the morphine-induced inhibition of gastrointestinal transit

J. Kamei; M. Ohsawa; M. Misawa; H. Nagase; Y. Kasuya

Effect of diabetes on the morphine-induced inhibition of gastrointestinal transit

J. Kamei
, M. Ohsawa
, M. Misawa
, H. Nagase
, Y. Kasuya

Hoshi University

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

The effect of diabetes on the morphine-induced inhibition of gastrointestinal transit was examined in mice. Morphine dose-dependently inhibited gastrointestinal transit after s.c. administration in both non-diabetic mice and diabetic mice. There was no significant difference between the ED₅₀ values for this antitransit effect of morphine in non-diabetic and diabetic mice. The gastrointestinal antitransit effect of morphine was significantly antagonized by pretreatment with β-funaltrexamine (40 mg/kg, s.c.), a selective μ-opioid receptor antagonist, in both non-diabetic and diabetic mice. However, pretreatment with naloxonazine (35 mg/kg, s.c.), a selective μ₁-opioid receptor antagonist, had no effect on the antitransit properties of morphine. These results suggest that diabetes failed to alter the μ₂-opioid receptor-mediated antitransit effect of morphine.

Original language	English
Pages (from-to)	165-169
Number of pages	5
Journal	Japanese Journal of Psychopharmacology
Volume	15
Issue number	2
State	Published - 1995
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

β-funaltrexamine
diabetes
gastrointestinal transit
morphine
naloxonazine

Cite this

@article{f1f272156d944e60a92954d514272a1f,

title = "Effect of diabetes on the morphine-induced inhibition of gastrointestinal transit",

abstract = "The effect of diabetes on the morphine-induced inhibition of gastrointestinal transit was examined in mice. Morphine dose-dependently inhibited gastrointestinal transit after s.c. administration in both non-diabetic mice and diabetic mice. There was no significant difference between the ED50 values for this antitransit effect of morphine in non-diabetic and diabetic mice. The gastrointestinal antitransit effect of morphine was significantly antagonized by pretreatment with β-funaltrexamine (40 mg/kg, s.c.), a selective μ-opioid receptor antagonist, in both non-diabetic and diabetic mice. However, pretreatment with naloxonazine (35 mg/kg, s.c.), a selective μ1-opioid receptor antagonist, had no effect on the antitransit properties of morphine. These results suggest that diabetes failed to alter the μ2-opioid receptor-mediated antitransit effect of morphine.",

keywords = "β-funaltrexamine, diabetes, gastrointestinal transit, morphine, naloxonazine",

author = "J. Kamei and M. Ohsawa and M. Misawa and H. Nagase and Y. Kasuya",

year = "1995",

language = "英語",

volume = "15",

pages = "165--169",

journal = "Japanese Journal of Psychopharmacology",

issn = "1340-2544",

publisher = "John Wiley \& Sons Inc.",

number = "2",

}

TY - JOUR

T1 - Effect of diabetes on the morphine-induced inhibition of gastrointestinal transit

AU - Kamei, J.

AU - Ohsawa, M.

AU - Misawa, M.

AU - Nagase, H.

AU - Kasuya, Y.

PY - 1995

Y1 - 1995

N2 - The effect of diabetes on the morphine-induced inhibition of gastrointestinal transit was examined in mice. Morphine dose-dependently inhibited gastrointestinal transit after s.c. administration in both non-diabetic mice and diabetic mice. There was no significant difference between the ED50 values for this antitransit effect of morphine in non-diabetic and diabetic mice. The gastrointestinal antitransit effect of morphine was significantly antagonized by pretreatment with β-funaltrexamine (40 mg/kg, s.c.), a selective μ-opioid receptor antagonist, in both non-diabetic and diabetic mice. However, pretreatment with naloxonazine (35 mg/kg, s.c.), a selective μ1-opioid receptor antagonist, had no effect on the antitransit properties of morphine. These results suggest that diabetes failed to alter the μ2-opioid receptor-mediated antitransit effect of morphine.

AB - The effect of diabetes on the morphine-induced inhibition of gastrointestinal transit was examined in mice. Morphine dose-dependently inhibited gastrointestinal transit after s.c. administration in both non-diabetic mice and diabetic mice. There was no significant difference between the ED50 values for this antitransit effect of morphine in non-diabetic and diabetic mice. The gastrointestinal antitransit effect of morphine was significantly antagonized by pretreatment with β-funaltrexamine (40 mg/kg, s.c.), a selective μ-opioid receptor antagonist, in both non-diabetic and diabetic mice. However, pretreatment with naloxonazine (35 mg/kg, s.c.), a selective μ1-opioid receptor antagonist, had no effect on the antitransit properties of morphine. These results suggest that diabetes failed to alter the μ2-opioid receptor-mediated antitransit effect of morphine.

KW - β-funaltrexamine

KW - diabetes

KW - gastrointestinal transit

KW - morphine

KW - naloxonazine

UR - https://www.scopus.com/pages/publications/0029012126

M3 - 記事

C2 - 7796321

AN - SCOPUS:0029012126

SN - 1340-2544

VL - 15

SP - 165

EP - 169

JO - Japanese Journal of Psychopharmacology

JF - Japanese Journal of Psychopharmacology

IS - 2

ER -

Effect of diabetes on the morphine-induced inhibition of gastrointestinal transit

Abstract

UN SDGs

Keywords

Other files and links

Fingerprint

Cite this